Topic
The London-based multinational drugmaker, also known as GSK, supplies key products such as vaccines in China, as well as drugs for lung disease and cancer. In 2013, the company was targeted by Chinese authorities over alleged corruption, price-fixing and quality controls.
Marty Moore, founder of Meissa Vaccines, says nasal sprays could be the future of the fight against Covid-19 and its variants by building better protection where the battle begins.
The agreement has the potential to reduce the UK’s reliance on overseas vaccine supplies amid a spat with the EU over exports.
Shanghai-based Genor Biopharma plans to seek regulatory approval for coprelotamab to be used in China on late-stage breast cancer patients.
Stada Arzneimittel, owned by private equity firms Bain Capital and Cinven, is turning to China to enhance its supply security and boost sales presence in Asia’s biggest pharmaceutical market.
Briton Peter Humphrey and his wife, Yu Yingzeng, were sentenced in China in 2014 for illegally obtaining and selling private records of Chinese citizens.
After more than three decades in development and almost US$1 billion in investment, the new vaccine began to be distributed in Lilongwe, the nation’s capital.
At a closed-door trial held last month in Hunan province, one-time high-flying business executive Mark Reilly was handed a three-year suspended prison sentence for his role in the largest corporate bribery scandal involving a foreign firm in China.
When Cathy Palmer first came to Hong Kong as a US prosecutor more than 20 years ago, she was chasing heroin-smuggling triads who later sent a booby-trapped package to her Brooklyn office.
In the wake of the Chinese government's punishment of GSK and some of its former senior executives for corruption, multinationals are changing their behaviour and strategies in China, said industry observers.
China has imposed a record fine of three billion yuan (HK$3.78 billion) on British pharmaceuticals giant GlaxoSmithKline (GSK) for bribing doctors to use its drugs.
A US anti-bribery probe into GSK touched on the firm's Chinese consumer health care business in 2012, internal documents show, suggesting the drugmaker's compliance problems in China could go wider than previously revealed.
A year after his detention sent shockwaves through China's booming due-diligence industry, British corporate investigator Peter Humphrey admitted in a Shanghai court yesterday that he paid contractors for private information on Chinese citizens for almost a decade.
The British corporate investigator Peter Humphrey and his Chinese-American wife Yu Yingzeng were handed fines and jail sentences of two years in Shanghai on Friday after being convicted on charges of "illegally obtaining private information".
Briton Peter Humphrey and his American wife, Yu Yingzeng, face trial on Friday for illegally obtaining personal information of Chinese citizens.
The only child of corporate investigators Peter Humphrey and Yu Yingzeng has been allowed to visit his parents in their detention centre in Pudong, Shanghai.
Corporate sleuth Peter Humphrey believes he worked for the public good by helping victims of crime, according to a letter seen by the Post that he wrote to his son Harvey from prison.
Prosecutors have filed charges against British investigator Peter Humphrey and his American wife, after the couple were detained last year following work they did for GlaxoSmithKline.
The United States has expressed concern after its officials were barred from the Chinese trial of two investigators for British drugmaker GlaxoSmithKline who are accused of illegally buying and selling private information.
British corporate investigator Peter Humphrey and his Chinese-born wife, Yu Yingzeng, will go on trial in Shanghai on July 29.
GlaxoSmithKline on Sunday confirmed the existence of an intimate video recording of its former China head, Mark Reilly, The Sunday Times reported.
The mainland's crackdown on corruption in the pharmaceutical sector has frightened foreign executives so much that some fear they could be jailed and have asked their lawyers if they should leave the country for six months.
The British Serious Fraud Office has opened formal criminal investigation into the commercial practices of GlaxoSmithKline in "numerous" countries.